10101677OCT On a Patient-Used System (OCTOPUS) - A personal eye scanning device to cut clinical burden of chronic retinal conditionsClosedCollaborative R&DInnovate UKAge-related macular degeneration (AMD) is the leading cause of sight loss in the developed world. It affects 1 in 4 over 60s. Patients with the wet form of the disease (wetAMD) can receive anti-VEGF injections to slow progression, however this requires regular monitoring of their condition through optical coherence tomography (OCT) eye scans. OCT systems are expensive, fragile and bulky, so are restricted to specialist settings. This prevents patients being scanned frequently enough meaning probabilistic treatment schedules are adopted. Some patients are heavily overtreated, others are undertreated, however the longer it takes for changes in the patient's condition to be identified, the longer it takes for anti-VEGF to be effective. Delays in treatment when required have been shown to cause irreversible sight loss. Siloton's personal OCT system will enable patients to self-scan in the home, meaning anti-VEGF can be administered exactly when required, not just when they are able to access a hospital OCT. This will reduce sight loss in the undertreated and save the NHS money, both from overtreating other patients and from monitoring visits. Predicted cost savings to the NHS would be ~£900m/year. At the core of Siloton's technology is a photonic chip, which allows a portable and patient-centred OCT device to be developed. This proprietary chip has been developed by Siloton and is one of the most advanced of its kind in the world. The focus of this project is to take this core device and construct an imaging system capable of demonstrating the use of the product by patients. This will be a world first for a patient being imaged with a chip of this kind. The outcome of this project will see a full prototype developed by Siloton including the supporting hardware and software for patient self-imaging. Siloton will utilise this device in an early patient study at Bristol Eye Hospital to investigate the quality of the images patients produce when self imaging. This project will be a significant advancement of Siloton's capabilities and will take one step closer to seeing a radical change in the way patients with AMD are treated for their condition - ultimately saving sight and the NHS significant resources.